U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Secretory uterine corpus endometrioid adenocarcinoma

MedGen UID:
690079
•Concept ID:
C1266057
•
Neoplastic Process
Synonyms: Endometrial Endometrioid Adenocarcinoma, Secretory Variant; endometrial endometrioid adenocarcinoma, secretory variant; Endometrioid adenocarcinoma, secretory variant; Secretory Uterine Corpus Endometrioid Adenocarcinoma; secretory uterine corpus endometrioid adenocarcinoma
SNOMED CT: Endometrioid adenocarcinoma, secretory variant (128680006)
 
Monarch Initiative: MONDO:0004174

Definition

An endometrioid adenocarcinoma arising from the endometrium. Morphologically it is characterized by the presence of malignant glandular cells containing glycogen vacuoles which are usually subnuclear and reminiscent of early secretory endometrium. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVSecretory uterine corpus endometrioid adenocarcinoma

Recent clinical studies

Etiology

PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F, Watanabe J, Hata H, Fujisawa T, Kamata Y, Nishimura Y, Jobo T, Kuramoto H
J Cancer Res Clin Oncol 2004 Mar;130(3):161-8. Epub 2003 Dec 20 doi: 10.1007/s00432-003-0517-8. PMID: 14689303

Diagnosis

Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects.
Clement PB, Young RH
Adv Anat Pathol 2002 May;9(3):145-84. doi: 10.1097/00125480-200205000-00001. PMID: 11981113

Prognosis

Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J, Nishizaki R, Jobo T, Kamata Y, Hata H, Nishimura Y, Fujisawa T, Okayasu I, Kuramoto H
Int J Gynecol Pathol 2004 Jul;23(3):234-40. doi: 10.1097/01.pgp.0000130050.27266.9a. PMID: 15213599
Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters.
Watanabe J, Sato H, Kanai T, Kamata Y, Jobo T, Hata H, Fujisawa T, Ohno E, Kameya T, Kuramoto H
Br J Cancer 2002 Jul 1;87(1):81-5. doi: 10.1038/sj.bjc.6600434. PMID: 12085261Free PMC Article

Clinical prediction guides

Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J, Nishizaki R, Jobo T, Kamata Y, Hata H, Nishimura Y, Fujisawa T, Okayasu I, Kuramoto H
Int J Gynecol Pathol 2004 Jul;23(3):234-40. doi: 10.1097/01.pgp.0000130050.27266.9a. PMID: 15213599
PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F, Watanabe J, Hata H, Fujisawa T, Kamata Y, Nishimura Y, Jobo T, Kuramoto H
J Cancer Res Clin Oncol 2004 Mar;130(3):161-8. Epub 2003 Dec 20 doi: 10.1007/s00432-003-0517-8. PMID: 14689303
Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters.
Watanabe J, Sato H, Kanai T, Kamata Y, Jobo T, Hata H, Fujisawa T, Ohno E, Kameya T, Kuramoto H
Br J Cancer 2002 Jul 1;87(1):81-5. doi: 10.1038/sj.bjc.6600434. PMID: 12085261Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...